Literature DB >> 1607331

Comparison of gentamicin dosing regimens using an in-vitro model.

E J Begg1, B A Peddie, S T Chambers, D R Boswell.   

Abstract

An in-vitro model which simulates in-vivo pharmacokinetics was used to compare the efficacy against Pseudomonas aeruginosa of dosing regimens of gentamicin which achieve different peak/trough concentrations but use the same total dose over 24 h. First exposure to gentamicin produced a rapid bactericidal effect which was proportional to the initial peak concentration. Subsequent doses of gentamicin produced a smaller bactericidal effect. Regrowth occurred with all dosing regimens, even after very high initial concentrations (26 mg/L). The time to reach bacterial counts above starting values was prolonged in relation to peak concentrations. Regrowth was also demonstrated in continuous infusion experiments which maintained very high concentrations (26 mg/L), although an inhibitory effect was evident compared with single dose experiments and the experiments mimicking in-vitro pharmacokinetics. There was little evidence of a post-antibiotic effect. The data supports the use of larger initial and longer interval bolus dosing compared with current recommendations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607331     DOI: 10.1093/jac/29.4.427

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.

Authors:  D Bugnon; G Potel; Y Q Xiong; J Caillon; M F Kergueris; P Le Conte; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach.

Authors:  D P Nicolau; R Quintiliani
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Postantibiotic effects of gentamicin and netilmicin on Serratia marcescens: effects on hydrophobicity and motility.

Authors:  L Majtánová; V Majtán
Journal:  Folia Microbiol (Praha)       Date:  2000       Impact factor: 2.099

4.  Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.

Authors:  Ami F Mohamed; Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

5.  Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.

Authors:  C R Rayner; L L Ioannides-Demos; J A Brien; L L Liolios; W J Spicer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.

Authors:  L L Ioannides-Demos; L Liolios; P Wood; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.

Authors:  M L Barclay; E J Begg; S T Chambers; D R Boswell
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.

Authors:  B J McGrath; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 9.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods.

Authors:  M E Klepser; M A Banevicius; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.